

PRESS RELEASE

Investment Survey Reveals Increased Confidence in Biotechnology Sector

Munich/Zug, 4 October 2005 – *Global Life Science Ventures (GLSV)* today released the results of a survey revealing increased optimism about the biotechnology sector and favourable long-term investment prospects, leading a massive 87% of investors and analysts to recommend investment in the biotechnology sector. The GLSV Biotech Investment Barometer was based on a questionnaire sent on 19 September to several hundred biotechnology company executives and members of the financial community located mainly in Switzerland and continental Europe. The survey, intended to gauge the climate for investment in biotechnology, is being presented at the Sachs Bloomberg Biotech in Europe Investor Forum, held in Zurich on 4-5 October, 2005.

Analysis of the 98 responses received, divided evenly between the biotechnology and investor/analyst groups, revealed several key conclusions:

- 46% of respondents were more optimistic about the biotech sector than 12 months ago, while only 11% were less so.
- The biotechnology market was considered on average to be fairly valued by the investors and analysts, while 57% of biotechnology company executives considered the market somewhat or very much undervalued.
- 77% of respondents agreed that the greatest value driver for biotechnology is developing therapeutics for untreatable medical conditions and filling the pharma industry's R&D pipeline.
- The greatest threats to the industry were considered to be:
 1. insufficient availability of funding to sustain development (45% of biotechnology respondents)
 2. the inability of companies to translate innovation into marketable drugs
- Interestingly, in the wake of several recent high-profile product withdrawals (Vioxx, Tysabri), safety issues were considered to be of moderate importance but not the overriding concern.
- The long-term perspectives for the biotech sector were judged highly or generally favourable by 87% of all respondents, and an equivalent 87% of the investor/analyst group were recommending investments in biotechnology.

Dr. Peter Reinisch, Partner at GLSV, commented: "The results of the GLSV Biotech Investment Barometer confirm that the industry is stabilising and is poised to realise its potential. As suggested by several respondents, selective investments in product-oriented companies with extensive proof-of-principle are likely to be rewarded with profitable returns."

Dr. Reinisch's presentation with the survey results is available on the GLSV website in the section "Download Area": www.glsv-vc.com



About Global Life Science Ventures:

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany and Switzerland, GLSV is dedicated to supporting early-stage companies originating from universities, scientific institutions or industry, but also invests in selected later-stage companies, including buy-outs. The group currently advises and manages funds totalling more than €200 million. GLSV has now financed 28 innovative life science companies, eleven of which have completed an exit through IPO, trade sale or M&A. GLSV has built up a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.

Global Life Science Ventures

Industry-born team – Proven track record – Global perspective

Germany

GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel. +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30
www.glsv-vc.com
mailbox@glsv-vc.com

Switzerland

GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel. +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

For additional information, please contact:

Rochat & Partners

Christophe Lamps
Tel. +41 22 718 37 46
Fax +41 22 786 54 58
E-mail: clamps@rochat-pr.ch